Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease

Joshua Kovach, Laura Ibsen, Michael Womack, David Steusse, Yuk M. Law

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Epoprostenol is a potent arterial vasodilator, and its administration by inhalation localizes its effects to the pulmonary circulation. In this case report, we describe a 3-month-old male patient with significant refractory pulmonary hypertension after pulmonary artery banding and placement of a Blalock-Taussig shunt. This patient continued to have significant hypoxic episodes despite maximal therapy with sedation, alkalinization, sildenafil, and inhaled nitric oxide. After the addition of inhaled epoprostenol, improvements in both clinical response and echocardiography-based hemodynamics were observed. The case supports a synergistic role among the agents in the treatment of pulmonary arterial hypertension from congenital heart disease.

Original languageEnglish (US)
Pages (from-to)194-198
Number of pages5
JournalCongenital Heart Disease
Volume2
Issue number3
DOIs
StatePublished - May 1 2007

Keywords

  • Congenital heart disease
  • Epoprostenol
  • Pulmonary arterial hypertension
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease'. Together they form a unique fingerprint.

  • Cite this